| Synthetic 8-ornithine-vasopressin, a clinically used vasoconstrictor, causes cardiac effects mainly via changes in coronary flow. | |
| | |
MedLine Citation:
|
PMID: 9113189 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: 8-ornithine-vasopressin (ornipressin, POR-8) is used as a potent peripheral vasoconstrictor mainly in combination with local anaesthetics. Because ornipressin causes vasoconstriction, any myocardial depressive effects could be caused indirectly by reduced myocardial perfusion secondary to coronary vasoconstriction, or directly by effects on myocardial tissue. METHODS: On isolated guinea pig hearts, we compared direct effects of ornipressin by perfusion at constant flow with indirect effects by perfusion at constant pressure by Langendorff technique. Ornipressin concentrations tested were 0.05, 0.1, 0.25, 0.5 and 1.0 IU/L (1 International Unit (IU) ornipressin = 2.8 micrograms) RESULTS: Coronary flow decreased significantly (P < 0.001) in concentration-dependent manner with ornipressin at constant pressure while AV conduction time and percentage O2 extraction (%O2E) increased and heart rate (HR), systolic left ventricular pressure (LVP) and myocardial O2 consumption (MVO2) decreased. Coronary perfusion pressure increased significantly with increasing ornipressin at constant coronary flow while HR and AV time were unchanged and LVP decreased only at the higher concentrations. At an identical or slightly reduced HR LVP product (RPP), MVO2 increased up to 27 +/- 6% at 1.0 IU/L ornipressin during constant flow perfusion. CONCLUSION: An increase in %O2E coupled with a decrease in coronary flow at constant pressure is consistent with myocardial depression secondary to reduced tissue perfusion. These ornipressin-induced effects are not evident at constant coronary flow except for a small but direct myocardial depressant effect on LVP at higher concentrations. The increase of MVO2 at constant flow, despite equal or even reduced work, is described as Gregg's phenomenon and it is probably due to an increase in coronary perfusion pressure during coronary vasoconstriction. Even though extrapolation of our results in humans is questionable, the current indication for use of ornipressin as vasoconstrictor may need to be reconsidered, especially in patients with reduced coronary reserve. |
| | |
Authors:
|
B M Graf; B Fischer; D F Stowe; Z J Bosnjak; E O Martin |
Related Documents
:
|
6109579 - Mechanisms mediating the coronary vascular response to behavioral stress in the dog. 3948369 - Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary art... 6818339 - Local vasoactivity of oxygen and carbon dioxide in the right coronary circulation of th... 1903819 - The interaction of vasodilating drugs and sympathetic blockade in normal and ischemic c... 3521579 - Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death. 21300709 - Conventional versus automated measurement of blood pressure in primary care patients wi... 17940709 - Cox-2 inhibitor nimesulide protects rat heart against oxidative stress by improving end... 1582789 - Retinal capillary hemodynamics, visual-evoked potentials, and pressure tolerance in nor... 3310639 - The inconsistent effects of calcium supplements upon blood pressure in primary hyperten... |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Acta anaesthesiologica Scandinavica Volume: 41 ISSN: 0001-5172 ISO Abbreviation: Acta Anaesthesiol Scand Publication Date: 1997 Mar |
Date Detail:
|
Created Date: 1997-06-27 Completed Date: 1997-06-27 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370270 Medline TA: Acta Anaesthesiol Scand Country: DENMARK |
Other Details:
|
Languages: eng Pagination: 414-21 Citation Subset: IM |
Affiliation:
|
Department of Anaesthesiology, University of Heidelberg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Atrioventricular Node / drug effects, physiology Coronary Circulation / drug effects* Depression, Chemical Guinea Pigs Heart / drug effects* Heart Rate / drug effects Myocardium / metabolism Ornipressin / pharmacology* Oxygen Consumption / drug effects Vasoconstrictor Agents / pharmacology* Ventricular Function, Left / drug effects Ventricular Pressure / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Vasoconstrictor Agents; 3397-23-7/Ornipressin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Changes in pulmonary mechanics during laparoscopic gastroplasty in morbidly obese patients.
Next Document: Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-he...